ERIN DUHAIME: Open Payments
NPI 1801041009 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$43,741 in 194 payments from 19 companies in 2025. Trend: 2023 $34,787 · 2024 $52,323 · 2025 $43,741
Speaker / faculty: $32,411Food & beverage: $5,151Travel & lodging: $3,629Consulting: $2,550
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 122 | $33,857 |
| Ferring Pharmaceuticals Inc. | 6 | $4,770 |
| Merck Sharp & Dohme LLC | 15 | $3,686 |
| Gilead Sciences, Inc. | 19 | $705 |
| ABBVIE INC. | 4 | $92 |
| PFIZER INC. | 4 | $86 |
| Theratechnologies Inc. | 3 | $82 |
| EMD Serono, Inc. | 3 | $70 |
| Astellas Pharma US Inc | 3 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $60 |
Products named: APRETUDE, DOVATO, REBYOTA, PIFELTRO, CABENUVA, Yeztugo, EGRIFTA, RUKOBIA.
Industry payments across TX — which companies pay providers there.
